To investigate the efficacy of acid suppression and pulmonary function in patients with asthma combined with acid reflux after clinical treatment with esomeprazole in combination with mosapride.

Patients with asthma combined with GERD (51 cases) hospitalized in the Respiratory and Critical Care Medicine Center of the People's Hospital of Xinjiang Uygur Autonomous Region from June 2020 to December 2021 were retrospectively analyzed and further divided into a control group (given conventional asthma treatment) and a study group (given esomeprazole combined with mosapride citrate on top of the control group) according to the treatment modality. General clinical information, lung function, GERDQ scale, asthma control test (ACT) score and Medical research association dyspnea scale (mMRC) were collected. Patients in both groups were treated for 8 weeks, and the improvement of the above indicators was collected and analyzed before and after treatment in both groups.

The improvement of acid reflux symptoms (GERD-Q) score, ACT score, and mMRC score indicators in the research group was significantly better than that in the control group, and the differences were statistically significant (P<0.05). Two groups of patients underwent pulmonary function analysis before and after treatment, and it was found that compared with the control group, the study group significantly improved lung function indicators: first second forced expiratory volume/forced vital capacity (FEV1/FVC), oxygen partial pressure, and carbon dioxide partial pressure. The differences were statistically significant (P<0.05). The total effective rate of the control group was 64.00%, while that of the study group was 88.46%, with a statistically significant difference (P<0.05).

The use of esomeprazole combined with mosapride citrate in the treatment of asthma combined with GERD is more effective than conventional treatment and deserves further clinical application.